Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CRNX
CRNX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRNX News
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
Jan 29 2026
NASDAQ.COM
Crinetics Prices 7.62M Share Offering at $45.95, Raising $350M
Jan 07 2026
Globenewswire
Crinetics Pharmaceuticals Reports Significant Results in CAH Study with Atumelnant
Jan 05 2026
Benzinga
Crinetics Pharmaceuticals Updates on Atumelnant Phase 2 Trial Results and PALSONIFY Commercialization
Jan 05 2026
NASDAQ.COM
Crinetics Pharmaceuticals to Update PALSONIFY™ Commercialization and Phase 2 Trial Results on January 5, 2026
Jan 04 2026
Globenewswire
Inaugural Week of CRNX Options Trading for February 2026
Dec 19 2025
NASDAQ.COM
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
PRnewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
Newsfilter
Crinetics CEO Scott Struthers to Present at J.P. Morgan Healthcare Conference
Dec 18 2025
Globenewswire
Crinetics to Present at 44th J.P. Morgan Healthcare Conference on January 13, 2026
Dec 18 2025
Newsfilter
First Patient Administered Atumelnant in Crinetics' Key Phase 3 Trial for CAH
Dec 12 2025
NASDAQ.COM
Crinetics Doses First Patient in CALM-CAH Phase 3 Trial for CAH Treatment
Dec 11 2025
Globenewswire
Crinetics Doses First Patient in CALM-CAH Phase 3 Trial for CAH Treatment
Dec 11 2025
Newsfilter
Crinetics Grants 39,575 Stock Options and 26,525 RSUs to New Employees
Dec 10 2025
Globenewswire
Crinetics Doses First Patient in Phase 1/2 Study of CRN09682 for SST2-Positive Tumors
Dec 03 2025
Newsfilter
Crinetics Launches Phase 3 Study of Paltusotine for New Use in Carcinoid Syndrome
Nov 21 2025
NASDAQ.COM
Show More News
